Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM.
Wilky BA, et al. Among authors: wu w.
J Clin Oncol. 2025 Jan 27:JCO2402524. doi: 10.1200/JCO-24-02524. Online ahead of print.
J Clin Oncol. 2025.
PMID: 39869830